Michael Berry

Chief Tech/Sci/R&D Officer at EVEREST MEDICINES LIMITED

59 year

Health Technology

Consumer Services

Profile

Michael Berry is currently the Chief Technology Officer at Everest Medicines Ltd.
He previously worked as the Senior Director of Bioprocess Development at Portola Pharmaceuticals, Director at ARCA biopharma, Director of Manufacturing Sciences & Technology at Novartis Vaccines & Diagnostics SL, and Vice President at Dynavax Technologies Corp.
He is also the Chief Technical Operations Officer at Clover Biopharmaceuticals Ltd.
Berry received his undergraduate degree from De Montfort University, his graduate degree from The University of Manchester, and his doctorate from the University of Manitoba.

Michael Berry active positions

Companies	Position	Start
EVEREST MEDICINES LIMITED	Chief Tech/Sci/R&D Officer	14/06/2023

All active positions of Michael Berry

Former positions of Michael Berry

Companies	Position	End
DYNAVAX TECHNOLOGIES CORPORATION	Corporate Officer/Principal	31/07/2017
PORTOLA PHARMACEUTICALS, INC.	Corporate Officer/Principal	31/01/2015
Novartis Vaccines & Diagnostics SL	Corporate Officer/Principal	31/08/2013
ARCA BIOPHARMA, INC.	Director/Board Member	30/04/2009
CLOVER BIOPHARMACEUTICALS, LTD.	Chief Tech/Sci/R&D Officer	-

See the detail of Michael Berry's experience

Training of Michael Berry

The University of Manchester	Graduate Degree
University of Manitoba	Doctorate Degree
De Montfort University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Berry's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	4
DYNAVAX TECHNOLOGIES CORPORATION	Health Technology
ARCA BIOPHARMA, INC.	Health Technology
EVEREST MEDICINES LIMITED	Health Technology
CLOVER BIOPHARMACEUTICALS, LTD.	Health Technology

Private companies	2
Portola Pharmaceuticals LLC Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.	Health Technology
Novartis Vaccines & Diagnostics SL

Private companies